Physician profile
Vikas Ghai
NPI 1831359108
$7,912.69
in general payments reported to CMS, 2019-2025
43 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $4,310 · 2021: $652 · 2022: $398 · 2023: $395 · 2024: $443 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118 · Education: $12.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.53 |
| Education | $12.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,738.30 | 2020-2024 | Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $755.34 | 2019-2024 | Opdivo |
| Pfizer INC. | $528.12 | 2019-2025 | |
| Janssen Biotech, INC. | $253.68 | 2019-2024 | Talvey, Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $214.72 | 2019-2025 | Injectafer |
| Amgen INC. | $208.85 | 2019-2022 | |
| Genentech USA, INC. | $197.78 | 2019-2024 | Itovebi, Phesgo, Polivy |
| Astellas Pharma US INC | $195.77 | 2023-2025 | Vyloy, Xospata, Padcev |
| Eisai INC. | $167.30 | 2020-2023 | |
| Exelixis INC. | $128.93 | 2019-2023 | Cabometyx |
| Merck Sharp & Dohme LLC | $128.35 | 2019-2025 | Keytruda, Keytruda Qlex |
| Vifor Pharma, INC. | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $109.56 | 2019-2020 | |
| Genzyme Corporation | $104.90 | 2019-2022 | |
| Beigene USA, INC. | $90.61 | 2020-2024 | Brukinsa |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Ghai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.